Description: Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir’s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks.
Home Page: cyteir.com
CYT Technical Analysis
128 Spring Street
Lexington,
MA
02421
United States
Phone:
857 285 4140
Officers
| Name | Title |
|---|---|
| Mr. Joseph S. Zakrzewski | Independent Investor & Independent Chairman |
| Dr. Markus F. Renschler M.D. | Pres, CEO & Director |
| Mr. Timothy Romberger | Independent Director |
| Dr. Paul Secrist Ph.D. | Chief Scientific Officer |
| Mr. Andrew W. Gengos | Chief Bus. Officer & Sec. |
| Dr. Kevin Mills Ph.D. | Co-Founder |
| Mr. David G. Gaiero | VP of Fin. |
| Ms. Lisa A. Hayes | VP of Investor Relations & Corp. Communications |
| Mr. Adam M. Veness Esq. | Gen. Counsel |
| Ms. Gale Cohen | VP of HR |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0.2752 |
| Price-to-Book MRQ: | 0.3037 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-06-18 |
| Fiscal Year End: | December |
| Full Time Employees: | 40 |